Prostate cancer treatment with pembrolizumab and olaparib yields promising outcomes: Study Dr. Kamal Kant Kohli12 Oct 2022 7:30 PM ISTUSA: According to a research published in the European Urology journal, pembrolizumab plus olaparib exhibited an antitumor effect and predicted...
AstraZeneca, Merck get Chinese nod for Lynparza to treat ovarian cancer Ruchika Sharma24 Sept 2022 3:24 PM ISTIn China, Lynparza is approved for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer as well as a 1st-line maintenance...
AstraZeneca Lynparza shows clinically meaningful survival benefit in 1st-line advanced ovarian cancer across two Phase III trials Ruchika Sharma11 Sept 2022 1:15 PM ISTOvarian cancer is one of the most common gynaecologic cancers, with a poor prognosis and a high mortality rate.
AstraZeneca, MSD get Japenese nod for breast cancer drug Lynparza Ruchika Sharma28 Aug 2022 11:45 AM ISTBreast cancer is the most diagnosed cancer worldwide with an estimated 2.3 million patients diagnosed in 2020.
AstraZeneca India breast cancer drug lynparza gets DCGI okay Isra Zaman22 Aug 2022 5:15 PM ISTAstraZeneca India, a science-led biopharmaceutical company, has announced that it has received a Drugs Controller General of India (DCGI) approval to...
DCGI nod to AstraZeneca India breast cancer drug Lynparza Ruchika Sharma20 Aug 2022 11:49 AM ISTEarly breast cancer is defined as the cancer confined to the breast with or without regional lymph node involvement and the absence of distant...
AstraZeneca- MSD gets EU nod for Lynparza to treat early-stage breast cancer Ruchika Sharma5 Aug 2022 5:23 PM ISTBreast cancer is the most diagnosed cancer worldwide with an estimated 2.3 million patients diagnosed in 2020.
AstraZeneca Olaparib gets CDSCO Panel okay for BRCA mutated HER2 negative breast cancer Dr. Divya Colin23 July 2022 6:00 PM ISTNew Delhi: Based on the scientific data provided by the drug maker AstraZeneca, the Subject Expert Committee (SEC) functional under Central Drug...
Setback: AstraZeneca proposal to market, manufacture Olaparib rejected by CDSCO panel Dr. Divya Colin23 April 2022 5:03 PM ISTNew Delhi: In a major setback to AstraZeneca, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has...
Olaparib benefits relapsed ovarian cancer patients, with BRCA1/2 mutation: Lancet Dr Satabdi Saha25 May 2021 9:30 AM ISTRecent research , put forth in The Lancet Oncology, has highlighted Olaparib to be effective in patients with relapsed ovarian cancer and BRCA1/2...
Positive results of phase III PROfound trial of Lynparza for metastatic castration-resistant prostate cancer: AstraZeneca, MSD Ruchika Sharma26 April 2020 9:00 AM ISTUS: AstraZeneca and MSD Inc. has announced further positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic...
